$AVTE News
Last published 1y ago
- 1y agoAVTEAerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related ProposalsPR NewswireAerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with...
- 1y agoAVTEAerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade BiosciencesPR NewswireAerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash...
- 1y agoAVTEAerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade BiosciencesPR NewswireAerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with...
- 1y agoAVTEDVAXHZNPMRNA+7Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual MeetingBusiness WireIssues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom
- 2y agoOBAVTEBMNTXKuehn Law Encourages OB, AVTE, B, and MNTX Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoAVTEAerovate Therapeutics and Jade Biosciences Announce Merger AgreementGlobeNewswireMerger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Jade Biosciences, the fourth company founded
- 2y agoAVTEAerovate Therapeutics to Explore Strategic AlternativesGlobeNewswireWALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary
- 2y agoAVTEInvestigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLCGlobeNewswireATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. ("Aerovate" or the "Company") (NASDAQ:AVTE) complied with federal securities laws. On June 17,
- 2y agoAVTEAerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial HypertensionGlobeNewswireWALTHAM, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) today announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical
- 2y agoAVTEAerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International ConferenceGlobeNewswireBaseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHCT continues at
- 2y agoAVTEAerovate Therapeutics Announces First Quarter Financial Results and Business HighlightsGlobeNewswireTopline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Enrollment continues into the Phase 3 portion of the
- 2y agoAVTEAerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International ConferenceGlobeNewswireWALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare
- 2y agoAVTEAerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsGlobeNewswireTopline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Completed enrollment in the Phase 2b portion and
- 2y agoAVTEAerovate Therapeutics Board of Directors Appoints Habib Dable as Board ChairGlobeNewswireWALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare
- 2y agoAVTEAerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial HypertensionGlobeNewswireTopline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial WALTHAM, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aerovate
- 2y agoAVTEAerovate Therapeutics Announces Third Quarter Financial Results and Business HighlightsGlobeNewswireWALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with
- 3y agoAVTEAerovate Therapeutics Announces Second Quarter Financial Results and Business HighlightsGlobeNewswireWALTHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with
- 3y agoAVTEAerovate Therapeutics Appoints Habib Dable To Its Board of DirectorsGlobeNewswireWALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with
- 3y agoAVTEAerovate Therapeutics to Present at Jefferies Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with
- 3y agoAVTEAerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International ConferenceGlobeNewswireDirect delivery of imatinib to the lungs in nonclinical species demonstrated increased lung exposure compared with oral or IV dosing Formulation impacted lung exposure with dry powder demonstrating greater lung exposure
- 3y agoAVTEAerovate Therapeutics Announces First Quarter Financial Results and Business HighlightsGlobeNewswireTopline Phase 2b data now expected in the second quarter of 2024 for the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH)More than 100 sites activated in 20 countries
- 3y agoAVTEAerovate Therapeutics Announces Full-Year 2022 Financial Results and Business HighlightsGlobeNewswireProgress continued on the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Expanded intellectual property portfolio with four issued patents in 2022 Management team
- 3y agoAVTEAerovate Therapeutics to Present at Cowen 43rd Annual Health Care ConferenceGlobeNewswireWALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with
- 3y agoAVTEAerovate Therapeutics Appoints Donald Santel To Its Board of DirectorsGlobeNewswireWALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with
- 3y agoAVTEAerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open ResearchGlobeNewswireWALTHAM, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with
- 3y agoAVTEAerovate Therapeutics Announces Third Quarter 2022 Financial ResultsGlobeNewswireWALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with
- 4y agoAVTEAerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022GlobeNewswireWALTHAM, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) today presents the design of IMPAHCT (Inhaled iMatinib for Pulmonary Arterial Hypertension Clinical Trial; AV-101-002), a
- 4y agoAVTEAerovate Therapeutics Announces Second Quarter 2022 Financial ResultsGlobeNewswireWALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today
- 4y agoAVTEAerovate Therapeutics to Present at Jefferies Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary diseases, toda
- 4y agoAVTEAerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)GlobeNewswireAV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the pathophysiology of PAH PAH is an area of high unmet need, and currently approved therapies are lim
- 4y agoAVTEAerovate Therapeutics Announces First Quarter 2022 Financial ResultsGlobeNewswireWALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today
- 4y agoAVTEAerovate Therapeutics Announces Full-Year 2021 Financial ResultsGlobeNewswireInitiated IMPAHCT, a global Phase 2b/Phase 3 trial of AV-101 for pulmonary arterial hypertension (PAH) in December 2021 Received FDA guidance in April 2021 that our Phase 2b/Phase 3 trial could support an NDA submission based on change in six minute wa
- 4y agoAVTEAerovate Therapeutics to Present at Cowen 42nd Annual Health Care ConferenceGlobeNewswireWALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary diseases, tod
- 4y agoAVTEAerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial HypertensionGlobeNewswireWALTHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary diseases, toda
- 4y agoAVTEAerovate Therapeutics Announces Third Quarter 2021 Financial ResultsGlobeNewswireWALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, toda
- 5y agoAVTEAerovate Therapeutics Announces Its Addition to the Russell 2000® IndexGlobeNewswireWALTHAM, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, ann
- 5y agoAVTEAerovate Therapeutics Announces Second Quarter 2021 Financial ResultsGlobeNewswireWALTHAM, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease,
- 5y agoAVTEFOXWFoxWayne, Aerami Therapeutics SPAC Deal Said Worth $195 MillionBloomberg
- 5y agoAVTEAerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewswireBOSTON, July 02, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announc
- 5y agoAVTEAerovate Therapeutics Announces Pricing of Upsized Initial Public OfferingGlobeNewswireBOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announc